Tocilizumab CAS NO.375823-41-9

We provide customized and high-quality Tocilizumab product for your project.

Tocilizumab is a humanized monoclonal antibody resistant against the interleukin-6 receptor (IL-6R). It is an immunosuppressive agent commonly used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis. Actemra (tocilizumab) 162 mg syringe for subcutaneous injection and Actemra 162 mg auto-injector for subcutaneous injection was approved in Japan for the treatment of Takayasu arteritis (TAK) and giant cell arteritis (GCA), as well as its intravenous injection was approved by FDA for severe cytokine release syndrome (CRS).